inotuzumab ozogamicin


Also found in: Wikipedia.

inotuzumab ozogamicin

A humanised CD22 linked to calicheamicin, which is being studied as a possible therapy for acute lymphoblastic leukaemia. Early data suggests that it can induce the desirable apoptosis of malignant cells at lower doses than those required for the CD33 immunotoxin gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia,
References in periodicals archive ?
for inotuzumab ozogamicin and granted it priority review.
TEHRAN (FNA)- In a randomized Phase III study of the drug inotuzumab ozogamicin, a statistically significant percentage of patients with acute lymphoblastic leukemia (ALL) whose disease had relapsed following standard therapies, qualified for stem cell transplants.
However, by 2020, the overall share of these drugs and regimens will be largely impacted by the launch of Graspa (ERYtechPharma), an innovative form of L-Asparaginase, followed by Marqibo (Talon Therapeutics) and Inotuzumab Ozogamicin (Pfizer, Inc.
Inotuzumab ozogamicin (CMC-544) is an antibody-drug conjugate composed of a humanized anti-CD22 antibody linked to calicheamicin, a potent cytotoxic agent [22].
Data to be presented on BOSULIF[R] (bosutinib) and Investigational Antibody Drug Conjugate, Inotuzumab Ozogamicin
Data will also be presented featuring inotuzumab ozogamicin, an antibody-drug conjugate (ADC) that is one of several investigational therapies in Pfizer's ADC portfolio.
M2 EQUITYBITES-February 23, 2017-Pfizer receives US FDA priority review designation for inotuzumab ozogamicin
today announced that investigational antibody-drug conjugate (ADC) inotuzumab ozogamicin received Breakthrough Therapy designation from the U.
hematological oncologists would prescribe Pfizer's inotuzumab ozogamicin to 40 percent of their patients with relapsed/refractory diffuse large B-cell lymphoma.
M2 EQUITYBITES-February 22, 2017-Pfizer files inotuzumab ozogamicin with the US FDA for treating acute lymphoblastic leukemia
Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin + Rituximab Followed by Stem Cell Transplantation in Relapsed/Refractory DLBCL Patients: Safety and Efficacy (Study 2005) (Poster, Abstract #2718, December 11)2
M2 PHARMA-February 23, 2017-Pfizer receives US FDA priority review designation for inotuzumab ozogamicin